Concord Drugs Q4 Results
- BSE: 538965
- NSE: -
- ISIN: INE858L01010
- Sector: Biotechnology & Drugs
BSE
77.48
0.57 (0.74%)
0.57 (0.74%)Volume2.74 K
Updated: Wed 11 Mar, 2026 | 15:28:23
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Concord Drugs Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 9.73 | 16.35 | -0.49% | 15.69 | -37.99% |
| Depreciation/ Amortization | 0.38 | 0.31 | 1.97% | 0.39 | -4.23% |
| Operating Income | 0.66 | 0.61 | -35.13% | -0.04 | 0.00% |
| Net Income | 0.04 | 0.22 | -82.84% | -0.34 | 0.00% |
| Net Income Before Taxes | 0.06 | 0.30 | -88.99% | -0.55 | 0.00% |
| Other Operating Expenses Total | 0.21 | 0.42 | -18.76% | 0.35 | -41.27% |
| Total Revenue | 10.39 | 16.97 | -3.78% | 15.64 | -33.57% |
| Selling/ General/ Admin Expenses Total | 1.24 | 1.24 | 23.31% | 1.69 | -26.75% |
| Diluted Normalized EPS | 0.04 | 0.16 | -83.53% | -0.34 | 0.00% |